Mesoporous Silicon Microparticles enhance robust immunity and protection against SARS-CoV-2 in mice and improves memory response in human PBMCs.

preprint OA: closed
Full text JSON View at publisher
AI-generated deep summary by claude@2026-07, 2026-07-04 · read from full text

The paper studied heteromorphous mesoporous silicon microparticles (MSMPs) used as an adjuvant for SARS-CoV-2 vaccination, with MSMPs conjugated to the spike S1 subunit (MSMPs-S1), tested in BALB/c and k18-hACE2 transgenic mice and in human peripheral blood mononuclear cells (PBMCs). MSMPs-S1 induced a robust, sustained humoral response in mice comparable to aluminum-based adjuvants, and after boosting increased IgG2a titers and neutralizing antibody levels while also elevating IFN-γ production in CD8+ T cells; in k18-hACE2 mice it reduced viral loads in lung and brain after lethal challenge, and in vitro it increased IFN-γ production in CD8+ T cells particularly with dendritic cells present. A major caveat stated by the authors is that this is a preprint that has not been peer reviewed. Relevance to endometriosis: the paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Silica-based materials have garnered interest as adjuvants due to their capacity to potentiate immune responses. In this study, we assess the immunogenicity and protective efficacy of heteromorphous mesoporous silicon microparticles (MSMPs) as an adjuvant in the context of SARS-CoV-2 vaccination. MSMPs conjugated with the S1 subunit of the spike protein (MSMPs-S1) induced a robust and sustained humoral immune response in BALB/c mice, comparable to that elicited by aluminum-based adjuvants. Following a booster dose, MSMPs-S1 significantly increased IgG2a titers and neutralizing antibody levels, exceeding those observed with Al(OH)₃-based formulations. Moreover, MSMPs-S1 enhanced cellular immunity, as indicated by elevated IFN-γ production in CD8⁺ T cells relative to the aluminum-adjuvanted group. In k18-hACE2 transgenic mice, vaccination with MSMPs-S1 conferred protection against a lethal SARS-CoV-2 challenge, with marked reductions in viral loads in both lung and brain tissues. In vitro, stimulation of human peripheral blood mononuclear cells (PBMCs) with MSMPs-S1 led to increased IFN-γ production in CD8⁺ T cells, particularly in the presence of dendritic cells. These findings support the potential of MSMPs as an effective adjuvant capable of promoting both humoral and cellular immunity, with relevance for the development of vaccines targeting emerging viral pathogens.
Full text 14,721 characters · extracted from preprint-html · click to expand
Mesoporous Silicon Microparticles enhance robust immunity and protection against SARS-CoV-2 in mice and improves memory response in human PBMCs. | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Mesoporous Silicon Microparticles enhance robust immunity and protection against SARS-CoV-2 in mice and improves memory response in human PBMCs. Ana López-Gómez, Irene Real-Arévalo, Elsa Mayol, Jana Ausio Cendra, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6977613/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Silica-based materials have garnered interest as adjuvants due to their capacity to potentiate immune responses. In this study, we assess the immunogenicity and protective efficacy of heteromorphous mesoporous silicon microparticles (MSMPs) as an adjuvant in the context of SARS-CoV-2 vaccination. MSMPs conjugated with the S1 subunit of the spike protein (MSMPs-S1) induced a robust and sustained humoral immune response in BALB/c mice, comparable to that elicited by aluminum-based adjuvants. Following a booster dose, MSMPs-S1 significantly increased IgG2a titers and neutralizing antibody levels, exceeding those observed with Al(OH)₃-based formulations. Moreover, MSMPs-S1 enhanced cellular immunity, as indicated by elevated IFN-γ production in CD8⁺ T cells relative to the aluminum-adjuvanted group. In k18-hACE2 transgenic mice, vaccination with MSMPs-S1 conferred protection against a lethal SARS-CoV-2 challenge, with marked reductions in viral loads in both lung and brain tissues. In vitro , stimulation of human peripheral blood mononuclear cells (PBMCs) with MSMPs-S1 led to increased IFN-γ production in CD8⁺ T cells, particularly in the presence of dendritic cells. These findings support the potential of MSMPs as an effective adjuvant capable of promoting both humoral and cellular immunity, with relevance for the development of vaccines targeting emerging viral pathogens . Vaccine Virus Cytotoxic Mesoporous Silicon Microparticles Full Text Supplementary Files SupplementaryFiguresDDTR.pptx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6977613","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":491825896,"identity":"102a22da-aad6-46ae-82e5-12c26e731476","order_by":0,"name":"Ana López-Gómez","email":"","orcid":"","institution":"Complutense University of Madrid: Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Ana","middleName":"","lastName":"López-Gómez","suffix":""},{"id":491825897,"identity":"d4aa8864-0b26-49d2-9ec0-d42c45993b43","order_by":1,"name":"Irene Real-Arévalo","email":"","orcid":"","institution":"Inmunotek SL","correspondingAuthor":false,"prefix":"","firstName":"Irene","middleName":"","lastName":"Real-Arévalo","suffix":""},{"id":491825898,"identity":"67a7d078-f990-45b9-8c54-b30445e76c4b","order_by":2,"name":"Elsa Mayol","email":"","orcid":"","institution":"Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Elsa","middleName":"","lastName":"Mayol","suffix":""},{"id":491825899,"identity":"d28a33ea-f7e1-4389-872d-30b0e86075a0","order_by":3,"name":"Jana Ausio Cendra","email":"","orcid":"","institution":"Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Jana","middleName":"Ausio","lastName":"Cendra","suffix":""},{"id":491825900,"identity":"d525d24a-3658-4087-982c-a5662fdc4ec8","order_by":4,"name":"Diego Laxalde-Fernández","email":"","orcid":"","institution":"Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Diego","middleName":"","lastName":"Laxalde-Fernández","suffix":""},{"id":491825901,"identity":"1fc094a8-6e0e-40b1-917f-4d8d3dcd29e2","order_by":5,"name":"Pablo Nogales-Altozano","email":"","orcid":"","institution":"CISA: Centro de Investigacion en Sanidad Animal","correspondingAuthor":false,"prefix":"","firstName":"Pablo","middleName":"","lastName":"Nogales-Altozano","suffix":""},{"id":491825902,"identity":"997355b4-20c8-4ba8-8093-027d5a0325fd","order_by":6,"name":"Benigno Rivas-Pardo","email":"","orcid":"","institution":"Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Benigno","middleName":"","lastName":"Rivas-Pardo","suffix":""},{"id":491825903,"identity":"3e467b7d-5be4-4830-98ef-300ec18362c8","order_by":7,"name":"Beatriz Amorós-Pérez","email":"","orcid":"","institution":"Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Beatriz","middleName":"","lastName":"Amorós-Pérez","suffix":""},{"id":491825904,"identity":"d8b5d64d-e672-4e94-b027-2a30d92ee3b9","order_by":8,"name":"Beatriz Martín-Adrados","email":"","orcid":"","institution":"Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Beatriz","middleName":"","lastName":"Martín-Adrados","suffix":""},{"id":491825905,"identity":"4f237e92-1b79-4a7f-8dae-b382aaab3de1","order_by":9,"name":"Ignacio Juárez","email":"","orcid":"","institution":"Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Ignacio","middleName":"","lastName":"Juárez","suffix":""},{"id":491825906,"identity":"b62946ec-be0f-4d65-a033-c0b558828866","order_by":10,"name":"Álvaro Martínez-Del-Pozo","email":"","orcid":"","institution":"Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Álvaro","middleName":"","lastName":"Martínez-Del-Pozo","suffix":""},{"id":491825907,"identity":"285718fb-de18-46ef-81dd-1003344c3280","order_by":11,"name":"Raul J. Martín-Palma","email":"","orcid":"","institution":"Universidad Autonoma de Madrid - Campus de Cantoblanco: Universidad Autonoma de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Raul","middleName":"J.","lastName":"Martín-Palma","suffix":""},{"id":491825908,"identity":"0d4704ad-5662-41ca-a8d7-f95e546d8a80","order_by":12,"name":"Noemí Sevilla","email":"","orcid":"","institution":"CISA: Centro de Investigacion en Sanidad Animal","correspondingAuthor":false,"prefix":"","firstName":"Noemí","middleName":"","lastName":"Sevilla","suffix":""},{"id":491825909,"identity":"51a296c9-03ec-4370-bcb7-53b2ab866807","order_by":13,"name":"Eduardo Martínez-Naves","email":"","orcid":"","institution":"Universidad Complutense de Madrid","correspondingAuthor":false,"prefix":"","firstName":"Eduardo","middleName":"","lastName":"Martínez-Naves","suffix":""},{"id":491825910,"identity":"4f7cabf1-6809-4f29-9da8-0b83fb3025be","order_by":14,"name":"Manuel Gómez del Moral","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAApUlEQVRIiWNgGAWjYBADOdK1GJOuJbGBaKW6/YuPbvjwZ1v6huOnExg+/CFCi9mNZ2k3Z/Dczt1wJncD48w2orScMbvNIwHUcoN3AzMvMc4Da/ljcDvdAKTlD1EOO99jdpsh4XYCWAsDG1G2sKXd7Dlw23Am0C8He4nyy/nDx278+HNbnu/42Y0PfhDjMAaJBAT7ADEaGBj4iVQ3CkbBKBgFIxgAAK7gQUkm0JAWAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0002-0642-8142","institution":"Universidad Complutense de Madrid Facultad de Medicina","correspondingAuthor":true,"prefix":"","firstName":"Manuel","middleName":"Gómez del","lastName":"Moral","suffix":""}],"badges":[],"createdAt":"2025-06-25 19:49:53","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6977613/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6977613/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":89471019,"identity":"1cacdcad-f13e-4a9c-bb84-d0dd764f1a86","added_by":"auto","created_at":"2025-08-20 09:25:22","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1253041,"visible":true,"origin":"","legend":"","description":"","filename":"MSMPsSARSCOV2VAXdef.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6977613/v1_covered_11f38ab1-ce63-4cbd-83a3-552f1f9c69d2.pdf"},{"id":87951359,"identity":"19da208b-124d-4046-a31d-d0d8abe14e9b","added_by":"auto","created_at":"2025-07-30 17:31:43","extension":"pptx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":197577,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryFiguresDDTR.pptx","url":"https://assets-eu.researchsquare.com/files/rs-6977613/v1/6c1454f3e4c0155bfcc88e31.pptx"}],"financialInterests":"","formattedTitle":"Mesoporous Silicon Microparticles enhance robust immunity and protection against SARS-CoV-2 in mice and improves memory response in human PBMCs.","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Vaccine, Virus, Cytotoxic, Mesoporous Silicon Microparticles","lastPublishedDoi":"10.21203/rs.3.rs-6977613/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6977613/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eSilica-based materials have garnered interest as adjuvants due to their capacity to potentiate immune responses. In this study, we assess the immunogenicity and protective efficacy of heteromorphous mesoporous silicon microparticles (MSMPs) as an adjuvant in the context of SARS-CoV-2 vaccination. MSMPs conjugated with the S1 subunit of the spike protein (MSMPs-S1) induced a robust and sustained humoral immune response in BALB/c mice, comparable to that elicited by aluminum-based adjuvants. Following a booster dose, MSMPs-S1 significantly increased IgG2a titers and neutralizing antibody levels, exceeding those observed with Al(OH)₃-based formulations. Moreover, MSMPs-S1 enhanced cellular immunity, as indicated by elevated IFN-γ production in CD8⁺ T cells relative to the aluminum-adjuvanted group. In k18-hACE2 transgenic mice, vaccination with MSMPs-S1 conferred protection against a lethal SARS-CoV-2 challenge, with marked reductions in viral loads in both lung and brain tissues. \u003cem\u003eIn vitro\u003c/em\u003e, stimulation of human peripheral blood mononuclear cells (PBMCs) with MSMPs-S1 led to increased IFN-γ production in CD8⁺ T cells, particularly in the presence of dendritic cells. These findings support the potential of MSMPs as an effective adjuvant capable of promoting both humoral and cellular immunity, with relevance for the development of vaccines targeting emerging viral pathogens\u003cem\u003e.\u003c/em\u003e\u003c/p\u003e","manuscriptTitle":"Mesoporous Silicon Microparticles enhance robust immunity and protection against SARS-CoV-2 in mice and improves memory response in human PBMCs.","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-07-30 17:31:38","doi":"10.21203/rs.3.rs-6977613/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"7825cd4c-6344-421e-b5d8-4d0f48e1ca09","owner":[],"postedDate":"July 30th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-08-20T09:17:12+00:00","versionOfRecord":[],"versionCreatedAt":"2025-07-30 17:31:38","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6977613","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6977613","identity":"rs-6977613","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00